Guide
Topical Clascoterone (CB-03-01): Side Effects, Results & Mechanism
Clascoterone (CB-03-01) is the first topical androgen receptor inhibitor evaluated for pattern baldness. Unlike oral finasteride, it targets androgen receptors directly in the scalp.
Mechanism of Action
Clascoterone competes directly with dihydrotestosterone (DHT) for binding sites at the dermal papilla androgen receptors. Because it acts locally and metabolizes into inactive cortexolone upon systemic absorption, systemic anti-androgen side effects are minimized.
Does Clascoterone Cause Sexual Side Effects?
Phase 3 clinical trial data demonstrates that topical clascoterone does not produce significant systemic anti-androgenic side effects (such as erectile dysfunction or gynecomastia) because systemic bio-availability is under 1%.
Frequently asked questions
Does clascoterone lower serum DHT?
No, clinical trials show topical clascoterone does not lower circulating serum DHT levels, preserving systemic hormone balance.
Can clascoterone be combined with minoxidil?
Yes, combining a topical androgen blocker with a growth stimulator like minoxidil addresses two separate biological pathways.
Related reading: full research article →
More guides
Informational only, not medical advice. Always consult a qualified clinician before starting or changing treatment.